Professor Mark Sleeman
Department of Physiology,
Monash University VIC 3800 Australia
Room F230, Building 13F (Physiology)
Tel: +61 3 990 52516
Fax: +61 3 990 29500
Dr. Sleeman was previously the Head of Metabolic Research at Regeneron Pharmaceuticals in Tarrytown, New York. Mark Sleeman was a recipient of a Juveniles Diabetes and Ruth Kirschstein Endocrine Fellowship at the University of Massachusetts in the laboratory of Dr Michael P. Czech where he studied mechanisms insulin-resistance/signaling. Dr Sleeman received his Ph.D. from Monash University and has published numerous papers on Type 2 Diabetes and Obesity in journals such as Cell Metabolism, Nature Medicine, Nature Genetics, PNAS, Journal of Biological Chemistry and Diabetes and is a member of numerous professional societies in USA and Australia.
For the past two decades he has been interested in the interplay between insulin resistance and obesity, and more specifically the molecular mechanisms behind the regulation food intake and body weight. To that end he and his colleagues have generated a large number of genetically modified animals to study these phenotypes. Recently, his research has focused on modulators of lipid metabolism and the development of fully human monoclonal antibody therapeutics for the potential treatment of metabolic disease.
• Associate Editor: Obesity & Metabolism Journal
• Advisory Board Member, St John’s University, Institute for Biotechnology, Utopia Parkway, Queens, New York.
• Davis Foundation Scientific Review Committee, New York, NY Since 2009 (Focus on Anorexia Nervosa)
1. Lambert, P.D., Anderson, K.D., Sleeman M.W. J. Tan, A. Hijarunguru, A., Corcoran T.L., Murray, J.D., Thabet, K.E., Yancopoulos, G.D. & Wiegand, S.J. Ciliary Neurotrophic Factor Activates Leptin-like Pathways and Reduces Body Fat, without Cachexia or Rebound Weight Gain, even in Leptin-resistance Obesity. PNAS, USA 98(8) 4657, 2001.
2. M.W. Sleeman, K. K. Garcia, R. Liu, J.D. Murray, L. Malinova, M. Moncrieffe, G.D. Yancopoulos & S.J. Wiegand. Ciliary Neurotrophic Factor Improves Type 2 Diabetes, Hepatic Steatosis, with Profound Effects on Metabolic Rate, in db/db mice. PNAS, USA 100(24) 14297, 2003.
3. Wortley K.E, Anderson, K.D., Garcia K., Murray, JD., Malinova, L., Liu, R., Moncrieffe, M., Thabet, K., Cox, H.J., Yancopoulos, G.D., Wiegand S.J. & Sleeman, M.W. Genetic Deletion of Ghrelin Does Not Decrease Food Intake, but Influences Metabolic Fuel Preference. PNAS, USA 1001 (21) 8227, 2004.
4. Blüher, S. Stergios M., Bullen S.J., Kokkotou, E., Maratos-Flier, E., Wiegand, S.J., Sleeman, M.W. & Mantzoros, C.S. CNTFAx15alters energy homeostasis and decreases body weight in diet-induced obese and UCP1-DTA mice. Diabetes, 53 (11), 2004.
5. Lynn E. Macdonald, Katherine E. Wortley, Lori C. Gowen, Keith D. Anderson, Jane Murray, William T. Poueymirou, Mary V. Simmons, Dianna Barber, David M. Valenzuela, Aris N. Economides, Stanley J. Wiegand, George D. Yancopoulos, Mark W. Sleeman, Andrew J. Murphy. Resistance to Diet-Induced Obesity in Mice Globally Over-expressing OGH/GPB5. PNAS, USA 102 (7) 2496, 2005.
6. M.W. Sleeman, K-M. Lia, K.Wortley, L. Gowen, M.Gonzales, J.Kintner, K. Garcia, J. Murray, T. N. Stitt, S. J.Wiegand, G. D. Yancopoulos, & D. Glass. SHIP2 Deletion Confers Resistance to Diet Induced Obesity. Nature Medicine 11, 199-205, 2005.
6. Katherine E. Wortley, Keith D. Anderson, Jane D. Murray, Karen Garcia, Rong Liu, Lubomira Malinova, George D. Yancopoulos, Stanley J. Wiegand and Mark W. Sleeman. Transient pharmacodynamic effects of Recombinant Human Variant CNTF on orexigenic neuronal function and rebound hyperphagia following drug withdrawal. Obesity & Metabolism. 1 (1), 31-38, 2005.
7. Natasha L. Harvey, R. Sathish Srinivasan, Miriam E. Dillard,, Nicole C. Johnson, Kelli Boyd, Mark W. Sleeman and Guillermo Oliver. Lymphatic Vascular defects Results in Adult-Onset Obesity. Nature Genetics October 37(10); 1072-81, 2005.
8. Katherine E. Wortley, Juan-Pablo del Rincon, Jane D. Murray, Karen Garcia, Keiji Iida, Michael O. Thorner & Mark W. Sleeman. Absence of ghrelin protects against early-onset obesity. J. Clin. Invest. 11: 3573-3578, 2005.
9. Katherine E Wortley, Keith D. Anderson, Jason Yasenchak, Andrew Murphy, David Valenzuela, George D. Yancopoulos, Sabrina Diano, Stanley J. Wiegand and Mark W. Sleeman. Agouti-Related Protein-Deficient Mice Display An Age-Related Lean Phenotype. Cell Metabolism. 2: 421-427, 2005.
10. Sabrina Diano, Susan A. Farr, Ewan C. Mcnay, Steven Benoit, Alfonso Abizaid, F. Spencer Gaskin, William A. Banks, John E. Morley, Shirly Pinto, Jeffrey M. Friedman, Robert S. Sherwin, Mark W. Sleeman, Matthias Tschop and Tamas L. Horvath. Ghrelin increases hippocampal spine synapse density and memory performance. Nature Neuroscience 9, 381-388, 2006.
11. Xu J, Gowen L, Raphalides C, Hoyer KK, Weinger JG, Renard M, Troke JJ, Vaitheesyaran B, Lee WN, Saad MF, Sleeman MW, Teitell MA, Kurland IJ. Decreased hepatic futile cycling compensates for increased glucose disposal in the PTEN heterozygote mouse. Diabetes December 55: 3372-3380, 2006
12. Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD, Roth RH, Sleeman MW, Picciotto MR, Tschöp MH, Gao XB, Horvath TL. Ghrelin targets the ventral tegmentum to regulate food intake. J. Clin. Invest. December 116: 3229-3239, 2006
13. Münzberg H, Jobst EE, Bates SH, Jones J, Villanueva E, Leshan R, Björnholm M, Elmquist J, Sleeman M, Cowley MA, Myers MG Jr. Appropriate inhibition of orexigenic hypothalamic arcuate nucleus neurons independently of leptin receptor/STAT3 signaling. Journal of Neuroscience January 27(1) 69-74, 2007
14. Okamoto H, Latres E, Liu R, Thabet K, Murphy A, Valenzeula D, Yancopoulos GD, Stitt TN, Glass DJ, Sleeman MW. Genetic deletion of Tribble 3 (Trib-3) does not affect insulin sensitivity or glucose homeostasis. Diabetes 56 (5); 1350-1356, 2007
15. Torres R, Croll SD, Vercollone J, Reinhardt J, Griffiths J, Zabski S, Anderson KD, Adams,NC, Gowen L, Sleeman MW, Valenzuela DM, Wiegand SJ, Yancopoulos GD, Murphy AJ. Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses. Pain. Aug; 130(3):267-78, 2007
16. Faber CA, Dobolyi A, Sleeman M, Usdin TB. Distribution of tuberoinfundibular peptide of 39 residues and its receptor, the parathyroid hormone 2 receptor in the mouse brain. Journal of Comparative Anatomy. June 1;502 (4):563-83, 2007
17. Wortley KE, Garcia K, Okamoto H, Thabet K, Anderson KD, Shen V, Herman JP, Valenzuela D, Yancopoulos GD, Tschöp MH, Murphy A, Sleeman MW. PYY regulates bone turnover in rodents. Gastroenterology, Nov 133 (5): 1534-43, 2007
18. Wang Q, Elghazi L, Martin S, Martins I, Srinivasan RS, Geng X, Sleeman M, Collombat P, Houghton J, Sosa-Pineda B. Ghrelin is a novel target of Pax4 in endocrine progenitors of the pancreas and duodenum. Dev Dyn, Jan; 237(1):51-61, 2008
19. D. B. Fegley, A. Holmes, T. Riordan, C. A. Faber, J. R. Weiss, S. Ma, D. Valenzeula, A. Murphy, G.D. Yancopoulos, M. W. Sleeman & T. B. Usdin. Regulation of anxiety and fear by tuberoinfundibular peptide of 39 residues Accepted Biol Psych 2008.
20. Pfluger PT, Kirchner H, Günnel S, Schrott B, Perez-Tilve D, Fu S, Benoit SC, Horvath T, Joost HG, Wortley KE, Sleeman MW, Tschöp MH. Simultaneous deletion of ghrelin and its receptor increases motor activity and energy expenditure. Am J Physiol Gastrointest Liver Physiol Mar; 294(3): G610-82008, 2008
21. Nogueiras R, López M, Lage R, Perez-Tilve D, Pfluger P, Mendieta-Zerón H, Sakkou M, Wiedmer P, Benoit SC, Datta R, Dong JZ, Culler M, Sleeman M, Vidal-Puig A, Horvath T, Treier M, Diéguez C, Tschöp MH. Bsx, a Novel Hypothalamic Factor linking Feeding with Locomotor Activity, is Regulated by Energy Availability. Endocrinology Jun; 149(6): 3009-15, 2008
22. R. Raz, E. Gazzerro S. Stricker, J.L. Clor, H. Nistala, S. Zabski, R.C. Pereira, L. Stadmeyer, X. Wang, L. Gowen, M.W. Sleeman, G. D. Yancopoulos, E. Canalis, S. Mundlos, D.M. Valenzuela, A.N. Economides. Ror2W749X, a dominant brachydactyly B allele in humans, causes recessive brachydactyly in the mouse, indicates an effect of ROR2 in patterning the joints, and provides a model for recessive Robinow syndrome Development May 135(9): 1713-23, 2008
23. López M, Lage R, Saha AK, Pérez-Tilve D, Vázquez MJ, Varela L, Sangiao-Alvarellos S, Tovar S, Raghay K, Rodríguez-Cuenca S, Deoliveira RM, Castañeda T, Datta R, Dong JZ, Culler M, Sleeman M.W., Alvarez CV, Gallego R, Lelliott CJ, Carling D, Tschöp MH, Diéguez C, Vidal-Puig A. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. May; 7(5):389-99 2008.
24. Sleeman MW, Latres E. The CAMplexities of central ghrelin. Cell Metab. May; 7(5):361-2, 2008.
25. Blum I.D., Patterson Z., Khazall R., Lamont E.W., Sleeman M.W., Horvath TL, Abizaid A. Reduced anticipatory locomotor responses to scheduled meals in ghrelin receptor deficient mice. Neuroscience. 2009 Dec 1;164(2):351-9. Epub 2009 Aug 8.
26. Watson E, Fargali S, Okamoto H, Sadahiro M, Gordon RE, Chakraborty T, Sleeman M.W., Salton SR. Analysis of knockout mice suggests a role for VGF in the control of fat storage and energy expenditure. BMC Physiol. 2009 Oct 28;9:19.
27. Zhao T.J., Liang G., Li R.L., Xie X., Sleeman M.W., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Goldstein J.L., Brown M.S. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci U S A. 2010, April;107:7467-72..
28. Perez-Tilve D, Hofmann SM, Basford J, Nogueiras R, Pfluger PT, Patterson JT, Grant E, Wilson H, Granholm N, Arnold M, Trevaskis J, Butler A, Davidson W Woods SC, Benoit SC, Sleeman M.W., DiMarchi R., Hui DY, & Tschőp M.H. The central nervous system directly regulates circulating cholesterol. Nature Neuroscience 2010 Jul 13(7): 877-82